Showing results (51-60 of 160) with videos related to
Sort By:
Pageof 16
Journal of Clinical Pharmacology|February 18, 2010
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patientsSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.British Journal of Clinical Pharmacology|May 6, 2016
Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalationJens Markus Borghardt, Benjamin Weber, Alexander Staab, et al.CPT: Pharmacometrics & Systems Pharmacology|January 26, 2019
Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by AfatinibRonald Niebecker, Hugo Maas, Alexander Staab, et al.Current Medical Research and Opinion|January 3, 2012
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justificationAndreas Clemens, Sebastian Haertter, Jeffrey Friedman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2021
Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?Arthur J Van De Vyver, Estelle Marrer-Berger, Ken Wang, et al.Pharmaceutics|December 16, 2020
Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene InteractionsSimeon Rüdesheim, Jan-Georg Wojtyniak, Dominik Selzer, et al.Psychoneuroendocrinology|January 27, 2018
How to disentangle psychobiological stress reactivity and recovery: A comparison of model-based and non-compartmental analyses of cortisol concentrationsRobert Miller, Jan-Georg Wojtyniak, Lisa J Weckesser, et al.Cancer Chemotherapy and Pharmacology|February 14, 2014
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumorsMatthias Freiwald, Ulrike Schmid, Angele Fleury, et al.Pharmaceutical Research|December 30, 2009
Population in vitro-in vivo correlation model for pramipexole slow-release oral formulationsElena Soto, Sebastian Haertter, Michael Koenen-Bergmann, et al.Pharmaceutics|September 26, 2020
Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric PatientsLukas Kovar, Andreas Weber, Michael Zemlin, et al.Pageof 16